Please use a PC Browser to access Register-Tadawul
TransCode Therapeutics Announces First Patient Dosed In Third Cohort With Lead Candidate In Phase 1 Clinical Trial; No Significant Safety Or Dose Limiting Toxicities Reported In Cohorts 1 And 2; PK Data From Cohorts 1 And 2 Consistent With Preclin...
TransCode Therapeutics Inc Ordinary Shares RNAZ | 10.66 10.68 | -1.11% +0.19% Post |
Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2
- No significant safety or dose limiting toxicities reported in Cohorts 1 and 2
- PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Jan. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with TTX-MC138, its lead candidate. The Safety Review Committee monitoring the clinical trial unanimously approved opening of the third cohort based on its favorable review of Cohort 1 and 2 safety and pharmacokinetic (PK) data. Additional Cohort 3 patients have been scheduled. The dose administered to patients in the third cohort is approximately double the dose administered to those in the second cohort.
Several patients in the first and second cohort remain on study for continued treatment, receiving additional doses of TTX-MC138. No significant safety or dose limiting toxicities have been reported. Analyses of PK data and pharmacodynamic (PD) activity from Cohorts 1 and 2 is ongoing. To date, the analyses suggest that TTX-MC138 demonstrates a PK/PD profile consistent with preclinical results and results from TransCode's previous Phase 0 clinical trial. Specifically, results from Cohort 1 confirmed the Phase 0 observation that TTX-MC138 shows evidence of pharmacodynamic activity in the presence of high baseline expression of miR-10b, reaching a 66% inhibition at 24 hours after infusion, similar to that seen in the Phase 0 trial. Additionally, TTX-MC138 activity increased with the escalated dose administered in Cohort 2 and was consistent at subsequent administrations of TTX-MC138, suggesting a favorable pharmacokinetic profile.